Published 12 issues per year
ISSN Print: 1521-9437
ISSN Online: 1940-4344
Indexed in
A Randomized, Placebo-Controlled, Multicenter Study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in Patients with Advanced Lung Cancer
ABSTRACT
Preclinical studies have established that the polysaccharide fractions of Ganoderma lucidum (Ling Zhi, reishi mashroom) have potential antitumor activity. Recent clinical studies have demonstrated that G. lucidum polysaccharides enhanced host immune functions (e.g., enhanced natural killer cell activity) in patients with advanced solid tumor, although objective response was not observed. A randomized double-blind, placebo-controlled, multicenter clinical trial was conducted to evaluate the efficacy and safety of the G. lucidum polysaccharides, Ganopoly®, in patients with advanced lung cancer. Sixty-eight patients with histologically confirmed advanced lung cancer were enrolled. Eligibility criteria included con. rmation of diagnosis, objective measurable disease, a Karnofsky performance score і60, life expectancy of 12 weeks or greater, no recent or concomitant anticancer therapy, and informed consent. Patients were evaluated with respect to their extent of disease and quality of life (Karnofsky score), and hematologic and selected immunological and biochemical studies at baseline and after 12 weeks of treatment with oral Ganopoly or placebo at 600 mg three times daily. Patients in both groups were similar with respect to age, sex, treatment history, and lung tumor histology. Treatment with Ganopoly gave stable disease (SD) in 13 (13/37, 35.1%) lung cancer patients at the 12-week evaluation point, which was significantly greater than that of control group (7/31, 22.6%). In 32 assessable cancer patient, treatment of Ganopoly resulted in a significant increase (>10 scores) in the KPS scores in 16 patients (50.0%); 4 patients (14.3%) obtained significant increase in the KPS scores in the control group with 29 assessable patients (p < 0.05); and 9 (28.1%) and 7 (21.9%) patients receiving Ganopoly had unchanged and reduced KPS scores, respectively. Values were 13 (46.4%) and 11 (39.3%) in the control group. Palliative effects on cancer-related symptoms such as fever, cough, weakness, sweating and insomnia have been observed in 43.8.84.4% of cancer patients receiving Ganopoly, but only a small percentage (10.7.42.9%) of cancer patients receiving placebo demonstrated improved cancer-related symptoms. Administration of Ganopoly for 12 weeks resulted in a significant (p < 0.05) increase in lymphocyte mitogenic reactivity to concanavalin A, CD3 percentage, and natural killer cell activity; a marginal increase in the CD4 percentage and CD4/CD8 ratio; but a marginal reduction of CD8. However, all these immune parameters remained unchanged or decreased in the control group. Three episodes of mild toxicity (nausea: 2; insomnia: 1) were recorded in patients receiving Ganopoly, and one episode of toxicity (vomiting) was recorded in the control group. The results indicate that Ganopoly may have an adjunct role in the treatment of patients with advanced lung cancer. Further studies are needed to explore the optimum dosing, efficacy, and safety of Ganopoly when used alone or in combination with chemotherapy/radiotherapy.
-
Cheung P. C. K., The nutritional and health benefits of mushrooms, Nutrition Bulletin, 35, 4, 2010. Crossref
-
Yuen John W. M., Gohel Mayur Danny I., Anticancer Effects of Ganoderma lucidum: A Review of Scientific Evidence, Nutrition and Cancer, 53, 1, 2005. Crossref
-
Jin Xingzhong, Ruiz Beguerie Julieta, Sze Daniel Man-yeun, Chan Godfrey CF, Jin Xingzhong, Ganoderma lucidum(Reishi mushroom) for cancer treatment, in Cochrane Database of Systematic Reviews, 2012. Crossref
-
Herbal approaches to pathological states, in Principles and Practice of Phytotherapy, 2013. Crossref
-
Kulshreshtha Shweta, Mathur Nupur, Bhatnagar Pradeep, Mushroom as a product and their role in mycoremediation, AMB Express, 4, 1, 2014. Crossref
-
Sze Daniel M.-Y., Liu Hao, Boost Maureen V., Wong Raimond, Sagar Stephen, PHYTOTHERAPEUTICS FOR CANCER THERAPY, in Phytotherapies, 2015. Crossref
-
Fung Shin Yee, Tan Nget Hong, Fungi as a source of antitumour agents, in Fungal Biomolecules, 2015. Crossref
-
Pineda-Alegría Jesús Antonio, Sánchez-Vázquez José Ernesto, González-Cortazar Manases, Zamilpa Alejandro, López-Arellano María Eugenia, Cuevas-Padilla Edgar Josúe, Mendoza-de-Gives Pedro, Aguilar-Marcelino Liliana, The Edible MushroomPleurotus djamorProduces Metabolites with Lethal Activity Against the Parasitic NematodeHaemonchus contortus, Journal of Medicinal Food, 20, 12, 2017. Crossref
-
Hsu Kai-Di, Cheng Kuan-Chen, From nutraceutical to clinical trial: frontiers in Ganoderma development, Applied Microbiology and Biotechnology, 102, 21, 2018. Crossref
-
Wong Raimond, Sagar Stephen M., Supportive Cancer Care Using Chinese Medicine, in Supportive Cancer Care with Chinese Medicine, 2010. Crossref
-
O’Brien Kylie, Sali Avni, Additional Therapies and Innovative Technologies, in A Clinician's Guide to Integrative Oncology, 2017. Crossref
-
Ahmad Md Faruque, Ganoderma lucidum: A rational pharmacological approach to surmount cancer, Journal of Ethnopharmacology, 260, 2020. Crossref
-
Jeitler Michael, Michalsen Andreas, Frings Daniela, Hübner Marisa, Fischer Moritz, Koppold-Liebscher Daniela A., Murthy Vijay, Kessler Christian S., Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review, Frontiers in Pharmacology, 11, 2020. Crossref
-
Jin Xingzhong, Ruiz Beguerie Julieta, Sze Daniel Man-yuen, Chan Godfrey CF, Ganoderma lucidum (Reishi mushroom) for cancer treatment, Cochrane Database of Systematic Reviews, 2019, 1, 2016. Crossref
-
Kladar Nebojša V., Gavarić Neda S., Božin Biljana N., Ganoderma: insights into anticancer effects, European Journal of Cancer Prevention, 25, 5, 2016. Crossref
-
Venturella Giuseppe, Ferraro Valeria, Cirlincione Fortunato, Gargano Maria Letizia, Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials, International Journal of Molecular Sciences, 22, 2, 2021. Crossref
-
Zeb Mehreen, Lee Chow H., Medicinal Properties and Bioactive Compounds from Wild Mushrooms Native to North America, Molecules, 26, 2, 2021. Crossref
-
Shetab Boushehri Maryam A., Lamprecht Alf, TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings, Molecular Pharmaceutics, 15, 11, 2018. Crossref
-
Panda Sujogya Kumar, Sahoo Gunanidhi, Swain Shasank S., Luyten Walter, Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery, Pharmaceuticals, 15, 2, 2022. Crossref
-
Ahmad Rizwan, Riaz Muhammad, Khan Aslam, Aljamea Ahmed, Algheryafi Mohammad, Sewaket Deya, Alqathama Aljawharah, Ganoderma lucidum (Reishi) an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties , Phytotherapy Research, 35, 11, 2021. Crossref
-
Park Hye-Jin, Current Uses of Mushrooms in Cancer Treatment and Their Anticancer Mechanisms, International Journal of Molecular Sciences, 23, 18, 2022. Crossref